Breakthrough drug for heart failure now available in the UK

Novartis drug Entresto™ (sacubitril/valsartan) approved for use in adults with symptomatic chronic heart failure with reduced ejection fraction reduces mortality risk compared with current treatment according to study

Source: Pharmacy Europe - January 20, 2016 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Practical therapeutics Cardiovascular medicine Legislation & regulation Patient care British Society for Heart Failure chronic heart failure ejection fraction Entresto HFrEF Latest News mortality risk PARADIGM Source Type: news